FMP
Advaxis, Inc.
ADXS
PNK
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
0.0333 USD
-0.0667 (-200.3%)
About
ceo
Mr. Kenneth A. Berlin J.D.
sector
Healthcare
industry
Biotechnology
website
https://www.advaxis.comexchange
PNK
Description
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
CIK
0001100397
ISIN
US0076244062
CUSIP
007624307
Address
9 Deer Park Drive
Phone
609 452 9813
Country
US
Employee
20
IPO Date
May 8, 2020
Key Executives
Name
Title
Pay
Year Born
Ms. Irit Klipper-Avni M.A.
Vice President of Human Resources
0
N/A
Ms. Dana Gelbaum M.B.A., M.Sc.
GM & Chief Business Officer
0
1974
Mr. Kenneth A. Berlin J.D.
Chief Executive Officer, President & Dir...
736.29k
1964
As of December 31, 2024, the total employee count stands at 20, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
